Over the last couple of years we have seen a number of oncology CAR-T cell therapy companies who were either late or slow in clinical development pivot to autoimmune disease, especially after the proof of concept offered in refractory systemic erythematosus lupus (SLE) and lupus nephritis by Prof Georg Schett’s group in Erlangen.

On the lookout

On top of the autologous and allogeneic products, we have also seen a variety of in vivo approaches emerge in both oncology and autoimmune indications, often involving some form of RNA based approach with a lipid nanoparticle (LNP).

Several of the companies in this space have already been snapped up by big Pharma, including Capstan Therapeutics (AbbVie), Orna Therapeutics (Lilly), Esobiotec (AstraZeneca), and more recently, Kelonia Therapeutics (Lilly).

So who are the next tranche of companies coming up behind them we should be looking out for and how are they shaping out with the latest round of data reveals?

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers